Skip to content
Subscriber Only

Chinese Alzheimer’s Drug to Launch Global Trials Amid Skepticism

  • Producer Green Valley says doubts about drug ‘understandable’
  • Clinical trials in U.S. and Europe to commence in 2020

A newly approved Chinese drug for Alzheimer’s will start clinical trials in the U.S. and Europe next year as the country’s first novel therapy for the incurable disease seeks global legitimacy.

Shanghai Green Valley Pharmaceutical Co. plans to recruit around 2,046 patients with mild-to-moderate Alzheimer’s for trials at 200 sites across North America, Europe and Asia Pacific for 18 months, the company’s Vice President Li Jinhe said on Sunday.